

**HPTN 084-01 - Safety, Tolerability and Acceptability of Long-Acting Cabotegravir for the Prevention of HIV among Adolescent Females - A Sub-study of HPTN 084  
Atlas OLE Report - January 15, 2026  
Visit Cutoff Date: January 15, 2026  
Table 1 - OLE Disposition Summary by Site**

	<b>Overall</b>	<b>MU-JHU</b>	<b>Spilhaus</b>	<b>Ward 21</b>
Total participants enrolled in the blinded study	55	17	20	18
Total participants enrolled in OLE	49	15	19	15
Participants in Active Follow-up	1/49 (2.0%)	0/15 (0.0%)	1/19 (5.3%)	0/15 (0.0%)
In the Pregnancy Substudy	1/1 (100.0%)	0/0 (-%)	1/1 (100.0%)	0/0 (-%)
Not yet reached Week 96	0/1 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/0 (-%)
At or beyond Week 96	0/1 (0.0%)	0/0 (-%)	0/1 (0.0%)	0/0 (-%)
<hr/>				
In active follow-up <sup>1</sup> and on study product				
In active follow-up <sup>1</sup> and on study product	1/49 (2.0%)	0/15 (0.0%)	1/19 (5.3%)	0/15 (0.0%)
In active follow-up but permanently discontinued study product	0/49 (0.0%)	0/15 (0.0%)	0/19 (0.0%)	0/15 (0.0%)
<hr/>				
Terminated early in OLE	4/49 (8.2%)	1/15 (6.7%)	2/19 (10.5%)	1/15 (6.7%)
Participant refused further participation	1/4 (25.0%)	0/1 (0.0%)	1/2 (50.0%)	0/1 (0.0%)
Lost to follow-up	2/4 (50.0%)	0/1 (0.0%)	1/2 (50.0%)	1/1 (100.0%)
Other	1/4 (25.0%)	1/1 (100.0%)	0/2 (0.0%)	0/1 (0.0%)
<hr/>				
Scheduled study exit / OLE complete	44/49 (89.8%)	14/15 (93.3%)	16/19 (84.2%)	14/15 (93.3%)

<sup>1</sup> Active follow-up is defined as having not formally terminated from the study.